EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Development of a novel manufacturing process for highly purified and stable immunoglobulin M with enhanced plasma utilization

Wen‐Rong Xia, Bo‐Guang Jiang, Yi Zhong, Wei Liu, Gui‐Hong Li, Yang‐Li Lu, Dong‐Qiang Lin

Vox Sanguinis · 2026-11-09

DOI: 10.1111/vox.70414 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background and Objectives Immunoglobulin M (IgM) is a promising therapeutic agent. However, its production is limited by high molecular weight, complex structure and poor stability. This study aimed to develop a novel manufacturing process for high‐purity, stable plasma‐derived IgM while improving plasma utilization. Materials and Methods The flow‐through fraction from first‐step anion‐exchange chromatography (Step 1 AEX) in an intravenous immunoglobulin manufacturing process was used as the starting material. Second‐step AEX (Step 2 AEX) and third‐step mixed‐mode chromatography (Step 3 MMC) were used to remove impurities, including prekallikrein activator (PKA), immunoglobulin G (IgG), immunoglobulin A (IgA) and α2‐macroglobulin. The elution conditions for Step 2 AEX were optimized to improve IgM recovery and purity. Four resins were evaluated for Step 3 MMC, and separation conditions were optimized to increase IgM purity and recovery. Finally, formulation studies were conducted to improve IgM stability. Results The optimized conditions were stepwise elution for Step 2 AEX (0.4 M followed by 1.0 M sodium acetate), Capto Core 400 resin for flow‐through‐mode Step 3 MMC and loading at pH 7.8, conductivity 15.0 mS/cm and protein concentration 1.0% ( w / v ). Key impurities IgA and PKA were reduced to 0.184 ± 0.011 mg/mL and below the limit of detection (90%). By optimizing plasma utilization, this process represents a promising platform for next‐generation immunoglobulin therapies.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →